Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis

Stopped early · Not applicable · Has a placebo group

Conditions studied: Psoriasis

In brief

This is a randomized, double-blind study of excimer (308-nm UVB) laser added to either tazarotene 0.1% gel or acitretin 25 mg daily for plaque psoriasis. The primary objective of this study is to compare the improvement of psoriatic plaques with and without excimer laser (308-nm UVB) treatment, applied in a randomized and blinded fashion, in subjects on acitretin 25 mg or tazarotene gel 0.1% QD.

Key facts

Study ID

NCT01094717

Run by

University of Utah

People needed

13

Starts

2010-01-01

Expected to finish

2011-10-01

Last updated by the study team

2019-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must give written informed consent
• Must be at least 18 years old
• Must have been diagnosed with stable plaque type psoriasis covering between 1 and 5% BSA
• NPF-PS ≥8 (based additive scores averaged over all lesions for erythema, scale, and thickness range of score = 0-5)
• No systemic or phototherapy in the 4 wks prior to entering the study
• No topical therapy other than emollients (no corticosteroids, vitamin D analogs, vitamin A analogs) in the 2 wks prior to entering the study
• Women on tazarotene gel must not be pregnant nor planning to become pregnant during the study and must be on two forms of birth control
• Subjects known to not tolerate oral acitretin at 25 mg/day and women of child-bearing potential may be enrolled and treated with topical tazarotene gel 0.1%

You may not qualify if…

• Candidates will be excluded from study entry if any of the following exclusion criteria exist at the time of enrollment:
• Unstable disease
• Only treatable sites are in intertriginous areas or on face
• Subjects unable to tolerate frequency of visits
• NPF-PS severity score <8 additive score of erythema, scale, and thickness, averaged over all lesions
• History of inability to tolerate topical tazarotene 0.1% gel and or acitretin 25 mg/day
• Women of childbearing potential are excluded from the actretin arm of the study.

Where it is running

• University of Utah Department of Dermatology — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.